堪萨斯城 - 市值2216万美元的小型生物技术公司Cingulate Inc. (NASDAQ: CING )周二宣布，已获得美国食品药品监督管理局 (FDA)批准2025财年PDUFA费用减免，用于其新药CTx-1301的申请。

PDUFA Fee Waiver comes Days before Planned Submission of New Drug ApplicationKANSAS CITY, Kan., July 29, 2025 (GLOBE NEWSWIRE ...

Cingulate developed CTx-1301 using its precision timed release (PTR) drug delivery platform. The drug contains dexmethylphenidate, an FDA-approved stimulant used to treat ADHD. Patients with ADHD ...

Cingulate was issued a European patent for its lead asset CTx-1301 for the treatment of ADHD during the third quarter of 2024. This patent will include up to 30 European territories, including the ...

Cingulate, Inc. (NASDAQ:CING) is a clinical-stage biopharmaceutical company with a proprietary Precision Timed Release (PTR) drug delivery platform technology. The company, founded in 2013, aims ...

--Cingulate Inc., a biopharmaceutical company utilizing its proprietary Precision Timed Release™ drug delivery platform technology to build and advance a pipeline of next-generation ...

Cingulate Inc. (NASDAQ: CING), is a biopharmaceutical company utilizing its proprietary PTR drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical ...

Editor's Note: Cingulate had filed a FORM S-1 with the SEC on March 10. The filing could have been a reason for the stock movement pre-market on March 13, rather than the commercialization agreement.

View Cingulate, Inc. CING stock quote prices, financial information, real-time forecasts, and company news from CNN.

Cingulate has applied the technology to two attention-deficit hyperactivity disorder candidates and the anxiety prospect but has seen investor interest dwindle over the past year, a period in ...